OCULIS HOLDING AG

European Biotech Acquisition Corp. (Nasdaq: EBAC) is a blank-check company that completed its initial public offering in 2021, targeting acquisition opportunities in the European biotech and pharmaceutical sector. In October 2022, EBAC announced a definitive business combination agreement with Oculis Holding AG, a clinical-stage ophthalmology company headquartered in Zug, Switzerland. The transaction subsequently closed, marking EBAC's status as completed and bringing Oculis into the U.S. public markets. The deal represents a cross-Atlantic SPAC structure connecting a European life sciences target with Nasdaq-listed capital markets access. For the complete filing timeline, deal documents, and comparable transaction data, sign up for full access at SpacDesk.

SPAC Counterparty (1)